Latest / Peptides Weekly / Ep 2: Nearly one in six children taking GLP-1 drugs show nutritional deficiencies in a new study.

Transcript

Ep 2: Nearly one in six children taking GLP-1 drugs show nutritional deficiencies in a new study. · Peptides Weekly

• 0:00
  Nearly one in six children taking glp-1 drugs show nutritional deficiencies in a new study. This
• 0:06
  is Peptides Weekly, episode two, education and evidence, never-dosing advice. An observational
• 0:13
  analysis of insurance claims data linked glp-1 receptor agonists to documented nutritional
• 0:19
  deficiencies in nearly one in six children. The study examined real-world prescribing records
• 0:25
  rather than a controlled trial. Researchers tracked field prescriptions and subsequent laboratory
• 0:30
  results for vitamin and mineral shortfalls. No causal mechanism was established in the data set.
• 0:37
  The analysis covered multiple GLP-1 agents used for type-2 diabetes or weight management.
• 0:43
  Claims databases capture routine care but miss unrequited supplements or dietary changes.
• 0:49
  A Yale review of online platforms found multiple sites supplying GLP-1 medicines
• 0:54
  after only a questionnaire and without an in-person or video visit by a licensed clinician.
• 1:00
  The study documented the absence of required medical evaluation in the sales process.
• 1:06
  Researchers classified the model as direct-to-consumer access that bypasses standard oversight.
• 1:12
  Platforms required self-reported height, weight, and medical history but did not verify details with a prescriber.
• 1:19
  The review covered several high traffic sites operating in the United States.
• 1:23
  reports. No regulatory action was described in the report. Swedish Pharmacovigilans records
• 1:29
  show an increase in adverse reaction reports tied to semi-glutide in the most recent reporting
• 1:35
  period. The data come from the National Spontaneous Reporting System and do not include confirmed
• 1:41
  causality assessments. Reports included gastrointestinal events and other side effects already known
• 1:47
  from clinical trials. The National Agency collects voluntary submissions from health care professionals
• 1:52
  and patients. An investigative feature examined unregulated peptide products sold for recovery
• 1:58
  and performance. The reporting contrasted marketing claims with documented cases of contamination
• 2:04
  and adverse effects in users. No controlled human trials supported the promoted benefits for
• 2:10
  the products discussed. The article described products labeled for research use only that reached
• 2:16
  consumers through online vendors. Laboratory testing cited in the piece revealed inconsistent purity
• 2:22
  across batches. Cyclists and other athletes were among the users interviewed for the story.
• 2:28
  A laboratory study in cell and animal models identified IGF-2BP3 as a regulator that stabilizes
• 2:36
  NPY-1R messenger RNA and shifts macrophages toward an M1 phenotype linked to aneurysm rupture.
• 2:45
  The work used molecular assays and rodent aneurysm models. Human data were not reported.
• 2:50
  Researcher's measured changes in M6A modification on the NPY-1R transcript after IGF-2BP-3 knockdown.
• 3:00
  Macrophage polarization was assessed by surface markers and cytokine profiles.
• 3:06
  The pathway was tested in both in vitro cultures and in vivo aneurysm induction.
• 3:11
  This week's spotlight looks at semi-glutide and the broader GLP-1 receptor agonist class.
• 3:17
  Cemaglutide is a long-acting analogue of the gut hormone GLP1.
• 3:22
  It binds the GLP1 receptor on pancreatic beta cells to increase glucose-dependent insulin
• 3:28
  release and on alpha cells to suppress glucagon.
• 3:32
  The same receptor activation in the brain reduces appetite and slows gastric emptying.
• 3:38
  In the sustained 6-trial, 3,297 adults with type 2 diabetes at high cardiovascular risk
• 3:45
  received once-weekly subcutaneous semaglutide or placebo for 104 weeks.
• 3:51
  That result confirmed non-inferiority and suggested superiority.
• 3:56
  In the select trial, 17,604 adults with overweight or obesity but without diabetes
• 4:03
  received 2.4 mg weekly semaglutide or placebo for a mean 39.8 months.
• 4:10
  The same composite endpoint occurred in 6.5% versus 8.0%.
• 4:16
  That established a cardiovascular benefit in this population.
• 4:20
  The Pioneer program tested oral semi-glutide in more than 8,000 adults across eight phase
• 4:26
  three trials lasting up to 78 weeks.
• 4:30
  Doses of 7 mg and 14 mg once daily lowered HBA1C and body weight more than placebo.
• 4:38
  Citigliptin, Ampagliflosen, Lyraglutide, and Dulaglutide.
• 4:44
  Gastrointestinal events were the most frequent side effects and were usually transient.
• 4:49
  A post-hoc analysis of a 32-week randomized trial found that Semaglutide increased the
• 4:55
  reactive hyperimic index from baseline, but the change did not reach significance versus
• 5:00
  placebo.
• 5:01
  E-selectin fell significantly versus placebo, while other cell adhesion markers showed mixed
• 5:07
  responses. Cost effectiveness modeling using Sermount 5 head-to-head data estimated that maximum
• 5:14
  tolerated tears epitide produced lower total costs and higher quality adjusted lyphiers than
• 5:20
  maximum tolerated semi-glutide in adults with obesity or overweight without diabetes.
• 5:26
  Worth knowing that an observational analysis of insurance claims shows nutritional deficiencies
• 5:31
  appear in nearly one in six children prescribed GLP1 receptor agonists.
• 5:37
  That indicates a need for laboratory monitoring in this age group.
• 5:41
  Spontaneous reporting data from Sweden record a recent increase in adverse event filings
• 5:46
  for semi-glutide.
• 5:48
  That underscores the value of ongoing pharmacovigilance for approved GLP1 medicines.
• 5:54
  Laboratory work on IGF2BP3 and aneurysm rupture illustrates how basic peptide signaling research
• 6:01
  can identify new molecular targets. Those findings remain at the cell and animal stage.
• 6:07
  That's peptides weekly. This show is education, not medical advice.
• 6:12
  Talk to your own clinician before acting on anything you heard.
• 6:15
  I'm Patrick in Vancouver. See you next week.
• 6:18
  Quick tip from the network. Try omnivue central and South America next.
• 6:23
  The day across central and South America from Mexico to the southern cone.
• 6:27
  Every Narra Network show is free at NarraNetwork.com. The age of AI puts real
• 6:34
  builders on the phone with an AI host. Apply at NarraNetwork.com, age of AI
• 6:40
  apply. This episode used AI voice synthesis of my voice. Editorial selection and
• 6:46
  analysis are my own.